| URL | https://www.fiercepharma.com/manufacturing/catalen |
| Source | https://www.fiercepharma.com |
| Date Published | 01/26/2022 |
| Author Name | Joseph Keenan |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Catalent |
| Parent company | Catalent, Inc |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
| Year reshoring announced: | 2022 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 10 |
| City reshored to: | Malver |
| State(s) reshored to: | PA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Medical Equipment & Supplies |
| Product(s) reshored | Clinical and commercial scale jet milling |